Searched over 200M research papers
10 papers analyzed
These studies suggest that cancer can kill by evading immune responses and resisting treatments, although various therapies aim to kill or control cancer cells through different mechanisms.
20 papers analyzed
Cancer cells have developed sophisticated mechanisms to evade destruction by the host immune system. Research has identified a core set of genes and pathways that enable cancer cells to resist killing by cytotoxic T lymphocytes (CTLs). These genes and pathways are involved in the interferon response and tumor necrosis factor (TNF)-induced cytotoxicity, which are crucial for the immune system's ability to target and destroy cancer cells. Additionally, the autophagy pathway has been shown to help cancer cells resist CTL-mediated killing, highlighting the complexity of cancer cell survival mechanisms.
Traditional cancer treatments like chemotherapy and radiotherapy are designed to kill cancer cells by inducing apoptosis, a form of programmed cell death. However, recent evidence suggests that these treatments can also push cancer cells into a state of senescence, where they stop dividing but do not die. This indicates that the effectiveness of these treatments may not solely rely on killing cancer cells but also on halting their proliferation.
Beyond apoptosis, cancer cells can undergo other forms of programmed cell death, such as lysosomal-mediated cell death, necroptosis, and autophagy. These non-apoptotic pathways are interconnected and can be exploited pharmacologically to develop new cancer therapies. Understanding these pathways provides insights into how to induce cell death in cancer cells that are resistant to traditional treatments.
For decades, the primary goal of cancer treatment has been to kill cancer cells. However, this approach may have reached its limits. Some researchers argue that viewing cancer as a community of cells with deranged signaling and communication opens new avenues for treatment. Instead of focusing solely on killing cancer cells, therapies could aim to restore normal cellular functions and control cancer growth. This perspective suggests that some successful treatments may work by reasserting control over cancer cells rather than eradicating them entirely.
Despite advances in cancer treatment, cancer remains a leading cause of death. The overall survival rates for many cancers have only improved slowly over the years. This underscores the need for prevention and early detection strategies to complement treatment efforts. Identifying high-risk individuals and understanding the factors that predispose them to cancer are crucial for improving survival rates.
Cytotoxic lymphocytes, including cytotoxic T cells and natural killer (NK) cells, play a critical role in cancer immunotherapy. These immune cells can kill cancer cells through mechanisms such as granule exocytosis and death ligands. However, recent studies suggest that these cells can also induce non-apoptotic pathways of cell death, which may help overcome resistance to traditional therapies. This highlights the potential of immunotherapy to target cancer cells through multiple mechanisms.
Cancer can indeed kill, but the mechanisms by which it does so are complex and multifaceted. While traditional treatments aim to kill cancer cells, emerging research suggests that controlling cancer growth and restoring normal cellular functions may be equally important. Understanding the diverse pathways of cell death and the role of the immune system in targeting cancer cells provides new opportunities for developing effective cancer therapies.
Most relevant research papers on this topic
3 Citations